Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer

por Span, P N, Bussink, J, De Mulder, P H, Sweep, F C G J
Publicado 2007

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Geni...

por De Mulder, P. H., Oosterhof, G., Bouffioux, C., van Oosterom, A. T., Vermeylen, K., Sylvester, R.
Publicado 1995

Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.

por Verweij, J., Wanders, J., Gil, T., Schöffski, P., Catimel, G., te Velde, A., de Mulder, P. H.
Publicado 1996

Psychosocial interventions for patients with advanced cancer – a systematic review of the literature

por Uitterhoeve, R J, Vernooy, M, Litjens, M, Potting, K, Bensing, J, De Mulder, P, van Achterberg, T
Publicado 2004

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.

por Punt, C. J., van Herpen, C. M., Jansen, R. L., Vreugdenhil, G., Muller, E. W., de Mulder, P. H.
Publicado 1997

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

por Kruit, W. H., Punt, C. J., Goey, S. H., de Mulder, P. H., Gratama, J. W., Eggermont, A. M., Bolhuis, R. L., Stoter, G.
Publicado 1996

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

por Punt, C. J., Voest, E. E., Tueni, E., Van Oosterom, A. T., Backx, A., De Mulder, P. H., Hecquet, B., Lucas, C., Gerard, B., Bleiberg, H.
Publicado 1997

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tra...

por de Wit, R., Stoter, G., Sleijfer, D. T., Kaye, S. B., de Mulder, P. H., ten Bokkel Huinink, W. W., Spaander, P. J., de Pauw, M., Sylvester, R.
Publicado 1995

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)

por Fosså, S D, Paluchowska, B, Horwich, A, Kaiser, G, de Mulder, P H M, Koriakine, O, van Oosterom, A T, de Prijck, L, Collette, L, de Wit, R
Publicado 2005

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

por de Wit, R., Collette, L., Sylvester, R., de Mulder, P. H., Sleijfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Stoter, G.
Publicado 1998

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.

por Stouthard, J. M., Goey, H., de Vries, E. G., de Mulder, P. H., Groenewegen, A., Pronk, L., Stoter, G., Sauerwein, H. P., Bakker, P. J., Veenhof, C. H.
Publicado 1996

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous...

por de Wit, R., Sylvester, R., Tsitsa, C., de Mulder, P. H., Sleyfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Vermeylen, K., Stoter, G.
Publicado 1997